Highlights Revenue at Rs. 2,137 crores up by 6% Gross margins: 72.2%; EBITDA margins: 33.2% EBITDA at Rs. 711 crores was up by 11%. Profit before tax at Rs. 472 crores was up by 23%. Net profit after tax at Rs. 316 crores was up 2% India: India revenues at Rs 1,087 crores grew by 13% Underlying growth adjusted for dispatch related delays last year is at 16% As per secondary market data (AIOCD), Torrent’s Q2 FY22 growth was 19% versus IPM growth of 15% Torrent has outperformed the market in all its key therapies during the quarter. MR productivity for the quarter was Rs 9.9 lakhs with MR strength of 3,600 For H1 FY22, revenues were Rs 2,180 crores, up by 15%. United States: US revenues at Rs 284 crores, were down by 13%. Constant currency sales were $35 million. Sales were lower due to price erosion in the base business and lack of new approvals pending re-inspection of facilities. As on September 30, 2021, 53 ANDAs were pending approval with USFDA and 7 tentative approvals were received. 1 ANDA was approved during the quarter. For H1 FY22, revenues were Rs 550 crores, down by 21% (Constant currency sales: $71 million). Brazil: Brazil revenues at Rs 156 crores, were up by 21% Constant currency sales at R$ 109 million. Brazil BGx market growth is at 10% during the quarter. Growth was driven by momentum in the large brands combined with the strong launch of two new products. For H1 FY22, revenues were Rs 309 crores, up by 15% (Constant currency sales: R$ 218 million, up by 16%). Germany: Germany revenues at Rs 251 crores were down by 4% Constant currency sales were Euro 29 million. Growth during the quarter was mainly impacted due to covid induced supply delays and inventory normalization led by customer consolidation at market place. Secondary sales trend was in-line with market growth. For H1 FY22, revenues were Rs 510 crores, up by 1% (Constant currency sales: Euro 58 million). Result PDF